PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

Jess L. Kaplan  ¹     Athos Bousvaros  ²     Dan Turner  ³     Marla C. Dubinsky  ⁴     Wendy Komocsar  ⁵     Amy Larkin  ⁵     Jordan Johns  ⁵     Xin Zhang  ⁵     Cheryl Little  ⁵     Wallace Crandall  ⁵     Vipin Arora  ⁵     Jeffrey Hyams  ^6    
1 Mass General for Children, Boston, United States
² Boston Children’s Hospital, Boston, United States
³ Shaare Zedek Medical Center, Jerusalem, Israel
⁴ Mount Sinai Hospital, New York, United States
⁵ Eli Lilly and Company, Indianapolis, United States
⁶ Connecticut Children’s Medical Center, Hartford, United States

Topic
IBD

Session
IL-23: Many but different? (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)